Navigation Links
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO

es that regulatory filings to support initiation of this clinical trial will be completed by mid-year 2007. Kosan plans to initiate a larger, international Phase 2/3 trial of alvespimycin in combination with trastuzumab in patients with HER2-positive metastatic breast cancer later in 2007.

Kosan also plans to pursue development of alvespimycin as a treatment for patients with acute myeloid leukemia (AML).

Kosan is also testing alvespimycin delivered orally in a Phase 1 dose escalation trial on both daily and every other day schedules. While dose escalation continues in this trial, early results have shown prolonged stable disease in patients with fibrosarcoma, hemangioendothelioma, melanoma and renal cell carcinoma with a favorable side effect profile.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global devel
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:4/24/2015)...  Elekta has CE marked the latest version (v5.10) ... enabling European clinics to deliver a sophisticated radiation therapy ... 3D planning, IMRT, VMAT and stereotactic planning – all ... Monaco ® v5.10 provides significant planning ... in 3D planning as well as the addition of ...
(Date:4/23/2015)... April 23, 2015  ResMed Inc. (NYSE: RMD ... 31, 2015.  Revenue for the quarter was $422.5 million, ... March 31, 2014 (a 13 percent increase on a ... increase of 1 percent compared to the quarter ended ... quarter were $0.64, an increase of 2 percent compared ...
(Date:4/23/2015)... April 23, 2015 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2015 on Thursday, April 30, 2015, after ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ... can be accessed through a link that is posted on ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... 5, 2011 Express Scripts contributed more than $226 ... economic analysis of the company,s data by a university ... The economic impact study, presented today to state economic ... support 2,665 direct and indirect jobs in the state. ...
... NeuroVasx announced today that the FDA ... Humanitarian Use Device (HDE) for the treatment of large, ... most difficult to treat.  The HDE allows for the ... the U.S. (Logo: http://photos.prnewswire.com/prnh/20110405/CG77724LOGO ) ...
Cached Medicine Technology:Express Scripts Injects $226 Million Into Arizona Economy, Study Finds 2NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System 2
(Date:4/26/2015)... Indiana (PRWEB) April 26, 2015 Indiana ... service provider announces that Brotherhood Mutual Insurance Company has ... Armstrong, Manager of Network Infrastructure at Brotherhood Mutual Insurance ... and the service reliability Brotherhood Mutual needed. ... diversity, and IFN worked with us to ensure we ...
(Date:4/26/2015)... FL (PRWEB) April 26, 2015 A ... pieces of medical equipment from hospitals, surgery centers and ... of equipment will be sold including radiology, surgery, endoscopy, ... live auction will take place Tuesday, April 28th starting ... Lauderdale warehouse located at 5025 North Hiatus Rd., Sunrise, ...
(Date:4/26/2015)... In an article published last month ... head-neck biomechanics occurring during the use of handheld electronic devices ... determine that use of a tablet increases mechanical demand on ... - more than when the neck is in a neutral ... but pointing out the potential hazards of overuse of mobile ...
(Date:4/26/2015)... MidSouth Pain Treatment Center has announced ... Treatment Center is a comprehensive pain management center including ... two ambulatory surgery centers in Germantown and Southaven, and ... , Dr. Michael Steuer , founder of MidSouth ... people, and when I discovered that I could make ...
(Date:4/25/2015)... California (PRWEB) April 26, 2015 Avid ... search for original 1965 Rolling Stones Greensboro Coliseum concert posters. ... was part of the Stone's Second American Tour. ... Globe Poster Company out of Baltimore, Maryland. This poster ... the northeast and southern cites. Globe uses garish lettering ...
Breaking Medicine News(10 mins):Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2
... Enjoying the eating process without focus on dietary restrictions ... according to researchers who have unveiled a new and ... Competence Model, also known as ecSatter, was created by ... of Secrets of Feeding a Healthy Family, Kelcy ...
... Significant Data Detailed at a Late-Breaking Presentation at ... ... 18 Iomai,Corporation (Nasdaq: IOMI ) today announced that travelers ... be sickened as compared with travelers who receive a placebo,according to ...
... (NYSE: AGP ) today announced that it ... and Medicare Services (CMS) to offer both,Medicare Advantage ... plans to address the specialized needs of seniors ... currently coordinates care for approximately 5,000,individuals through Medicare ...
... N.C., Sept. 18 Contact centers have been,transformed ... movement,that has reps selling while conducting ongoing customer ... skills are critical for,converting service reps to sales ... Practices, LLC. Ninety-eight percent of the 57 ...
... Researchers at the University of Pennsylvania School of ... Quality (AHRQ) have developed a framework to help ... challenges of implementing health information technology (HIT) by ... and quality. , As documented in a ...
... WASHINGTON, Sept. 18, 2007 -- A long-term study found ... patients with life-threatening diseases, such as leukemia and lymphoma, ... Further, males are likely to recover from these changes ... compromised. In addition, neither male nor female long-term cancer ...
Cached Medicine News:Health News:Nutrition model stresses positive experience of eating 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 2Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 3Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 4Health News:Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study 5Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 2Health News:AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States 3Health News:Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills 2Health News:Unanticipated consequences of health-care information technology 2Health News:Sexual function affected by stem cell transplant according to long-term study 2Health News:Sexual function affected by stem cell transplant according to long-term study 3Health News:Sexual function affected by stem cell transplant according to long-term study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: